David Tsao Sells 20,000 Shares of Billiontoone (NASDAQ:BLLN) Stock

Billiontoone, Inc. (NASDAQ:BLLN) CTO David Tsao sold 20,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $102.27, for a total value of $2,045,400.00. Following the completion of the transaction, the chief technology officer directly owned 1,000 shares in the company, valued at $102,270. The trade was a 95.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Price Performance

Billiontoone stock opened at $105.15 on Friday. The company has a current ratio of 10.92, a quick ratio of 10.58 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $4.84 billion and a P/E ratio of 191.18. The business has a 50-day moving average of $89.56 and a 200-day moving average of $87.22. Billiontoone, Inc. has a 1 year low of $61.96 and a 1 year high of $138.70.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.33. The firm had revenue of $108.39 million for the quarter, compared to the consensus estimate of $95.81 million. The firm’s revenue was up 83.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.39) EPS. On average, equities analysts anticipate that Billiontoone, Inc. will post 0.93 EPS for the current year.

Analysts Set New Price Targets

BLLN has been the subject of a number of recent analyst reports. Guggenheim upped their price objective on shares of Billiontoone from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Weiss Ratings cut Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 5th. Wells Fargo & Company dropped their price target on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 5th. Wall Street Zen upgraded Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Finally, JPMorgan Chase & Co. boosted their price objective on Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $125.29.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Green Alpha Advisors LLC acquired a new stake in Billiontoone in the 4th quarter valued at approximately $436,000. FNY Investment Advisers LLC bought a new position in shares of Billiontoone during the 4th quarter worth approximately $497,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of Billiontoone in the fourth quarter valued at approximately $13,373,000. Baillie Gifford & Co. acquired a new stake in shares of Billiontoone in the fourth quarter valued at approximately $103,786,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Billiontoone in the fourth quarter worth $1,348,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.